“Yellen” Effect Boosts Markets-FED Policies Clarified
With Larry Summers dropping out as a likely candidate for FED Chairman the market may be assured of a continuation of current FED policy. The market sees no surprises in Janet Yellen who is a frontrunner, as she is current Vice Chairman and has been a voting member of of the Fed Open Market Committee (FOMC) since 2009. Yellen is favored by economists and Wall Street because she is perceived as more experienced in FED policy and less hawkish than Larry Summers.
Dow Jones and S&P Up 1%, but NASDAQ Lagging due Mainly to Apple Down 2.2%
The biotech sector hit new all time highs today as the IBB hit $211 but eased a bit to $208 still up 0.7% today and 52% YTD.Despite all time highs in biotech and a strong September the momentum has eased. The XBI is flat since last Monday. The Rayno Biopharma Portfolio has many winners today continuing Friday’s rally:
Achillion (ACHN $7.50) up 3%.
Alkermes (ALKS $35.50) up 3.5%.
Biogen Idec (BIIB $240) up 2.3%
Pharmacyclics (PCYC $118) up 1.33%.
Regeneron (REGN $294) up 1.68%.
Viropharma (VPHM $39.45) up 0.8% but gapped up from $30 on Friday on news of buyout interest from Sanofi (SNY) and Shire (SHPG). This is the second Rayno stock this month to rocket on buyout news. Astex soared from $6.50 to $8.50 on an Otsuka bid. It is interesting to note that a few analysts are saying that Astex (ASTX) assets were undervalued and sold too cheaply when few recognized value in the stock just 3 months ago at $4.50.
Rayno Diagnostic and Tools stocks were in a rally mode today : Cepheid (CPHD) up 1.5%-up 16% over 3 months, Neogen (NEOG) up 1.2%, laggard Qiagen (QGEN) up 2.4% and Thermo Fisher (TMO) up 1%.
No change in Rayno Life Science Portfolio with sector up over 50% YTD. 10 % cash.